Literature DB >> 27771488

Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis.

Barbara McKenzie1, Graeme Kay2, Kerr H Matthews2, Rachel Knott2, Donald Cairns2.   

Abstract

Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in the cells of all organs. It is treated by regular administration of the aminothiol, cysteamine. Corneal crystal deposition is one of the most troublesome complications affecting patients and requires the hourly administration of cysteamine eye drops. In an attempt to reduce this frequency and improve the treatment, the preformulation and evaluation of cysteamine containing gels is reported. Suitability for ophthalmic delivery was determined by analysis of rheology, bioadhesion, dissolution and stability. The results demonstrated that three polymers were suitable for ophthalmic delivery of cysteamine; namely sodium hyaluronate, hydroxyethyl cellulose and carbomer 934. Sodium hyaluronate displayed optimum performance in the preformulation tests, being pseudoplastic (reduction in apparent viscosity under increasing shear rate), bioadhesive, releasing cysteamine over 40min and displaying stability over time. In conclusion these results offer the possibility to formulate cysteamine in an ocular applicable gel formulation. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cysteamine; Cystinosis; Gel; Ophthalmic delivery; Preformulation

Mesh:

Substances:

Year:  2016        PMID: 27771488     DOI: 10.1016/j.ijpharm.2016.10.044

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  A sustained release cysteamine microsphere/thermoresponsive gel eyedrop for corneal cystinosis improves drug stability.

Authors:  Jorge Jimenez; Michael A Washington; Jayde L Resnick; Ken K Nischal; Morgan V Fedorchak
Journal:  Drug Deliv Transl Res       Date:  2021-02-04       Impact factor: 4.617

2.  The Ocular Status of Cystinosis Patients Receiving a Hospital Pharmacy-Made Preparation of Cysteamine Eye Drops: A Case Series.

Authors:  Susmito Biswas; Krishanthy Sornalingam
Journal:  Ophthalmol Ther       Date:  2018-12-05

Review 3.  Recent Trends in Assessment of Cellulose Derivatives in Designing Novel and Nanoparticulate-Based Drug Delivery Systems for Improvement of Oral Health.

Authors:  Khaled M Hosny; Hala M Alkhalidi; Waleed S Alharbi; Shadab Md; Amal M Sindi; Sarah A Ali; Rana B Bakhaidar; Alshaimaa M Almehmady; Eman Alfayez; Mallesh Kurakula
Journal:  Polymers (Basel)       Date:  2021-12-27       Impact factor: 4.329

Review 4.  Cysteamine hydrochloride eye drop solution for the treatment of corneal cystine crystal deposits in patients with cystinosis: an evidence-based review.

Authors:  Achini K Makuloluwa; Fatemeh Shams
Journal:  Clin Ophthalmol       Date:  2018-01-24

Review 5.  Latest Clinical Approaches in the Ocular Management of Cystinosis: A Review of Current Practice and Opinion from the Ophthalmology Cystinosis Forum.

Authors:  Susmito Biswas; Martha Gaviria; Luísa Malheiro; João Pedro Marques; Vincenzo Giordano; Hong Liang
Journal:  Ophthalmol Ther       Date:  2018-09-21

6.  Limitations and Challenges in the Stability of Cysteamine Eye Drop Compounded Formulations.

Authors:  Cristina Martín-Sabroso; Mario Alonso-González; Ana Fernández-Carballido; Juan Aparicio-Blanco; Damián Córdoba-Díaz; Federico Navarro-García; Manuel Córdoba-Díaz; Ana I Torres-Suárez
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.